 | Up a level |
Hoobehfekr, S. and Moghaddam, H.S. and Shalbafan, M. and Hashemi, M.G. and Pirmoradi, M.M. and Sakenian, A. and Poopak, A. and Kashefinejad, S. and Yarahmadi, M. and Akhondzadeh, S. (2021) Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry and Clinical Neurosciences, 75 (2). pp. 57-62.
Yousefzadeh, F. and Sahebolzamani, E. and Sadri, A. and Mortezaei, A. and Aqamolaei, A. and Mortazavi, S.H. and Shalbafan, M.R. and Ghaffari, S. and Alikhani, R. and Mousavi, S.B. and Naderi, S. and Shamabadi, A. and Jalilevand, S. and Akhondzadeh, S. (2020) 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control. International Clinical Psychopharmacology, 35 (5). pp. 254-262.
Ghaffari, S. and Ghobadi, A. and Jamshidi, A.H. and Mortazavi, S.H. and Naderi, S. and Aqamolaei, A. and Mortezaei, A. and Sahebolzamani, E. and Shamabadi, A. and Jalilvand, S. and Daraei, B. and Shalbafan, M.R. and Akhondzadeh, S. (2020) Cinnamomum tamala as an adjuvant therapy in the treatment of major depressive disorder: A double-blind, randomized, placebo-controlled clinical trial with placebo control. Advances in Integrative Medicine, 7 (3). pp. 141-147.
Borhannejad, F. and Shariati, B. and Naderi, S. and Shalbafan, M. and Mortezaei, A. and Sahebolzamani, E. and Saeb, A. and Hosein Mortazavi, S. and Kamalzadeh, L. and Aqamolaei, A. and Ali Noorbala, A. and Namazi-Shabestari, A. and Akhondzadeh, S. (2020) Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial. Journal of Clinical Pharmacy and Therapeutics, 45 (4). pp. 804-811.
Noorbala, A.A. and Saljoughian, A. and Bagheri Yazdi, S.A. and Faghihzadeh, E. and Farahzadi, M.H. and Kamali, K. and Faghihzadeh, S. and Hajebi, A. and Akhondzadeh, S. and Mousavi, M.T. (2020) Evaluation of drug and alcohol abuse in people aged 15 years and older in Iran. Iranian Journal of Public Health, 49 (10). pp. 1940-1946.
Araminia, B. and Shalbafan, M. and Mortezaei, A. and Shirazi, E. and Ghaffari, S. and Sahebolzamani, E. and Mortazavi, S.H. and Shariati, B. and Ardebili, M.E. and Aqamolaei, A. and Naderi, S. and Akhondzadeh, S. (2020) L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders, 267. pp. 131-136.
Ghajar, A. and Gholamian, F. and Tabatabei-Motlagh, M. and Afarideh, M. and Rezaei, F. and Ghazizadeh-Hashemi, M. and Akhondzadeh, S. (2018) Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Human Psychopharmacology, 33 (4).
Roohi-Azizi, M. and Torkaman-Boutorabi, A. and Akhondzadeh, S. and Nejatisafa, A.-A. and Sadat-Shirazi, M.-S. and Zarrindast, M.-R. (2018) Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice. Physiology and Behavior, 195. pp. 151-157.
Ghajar, A. and Khoaie-Ardakani, M.-R. and Shahmoradi, Z. and Alavi, A.-R. and Afarideh, M. and Shalbafan, M.-R. and Ghazizadeh-Hashemi, M. and Akhondzadeh, S. (2018) L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Psychiatry Research, 262. pp. 94-101.
Ghajar, A. and Khoaie-Ardakani, M.-R. and Shahmoradi, Z. and Alavi, A.-R. and Afarideh, M. and Shalbafan, M.-R. and Ghazizadeh-Hashemi, M. and Akhondzadeh, S. (2018) L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Psychiatry Research, 262. pp. 94-101.
Khalaj, M. and Saghazadeh, A. and Shirazi, E. and Shalbafan, M.-R. and Alavi, K. and Shooshtari, M.H. and Laksari, F.Y. and Hosseini, M. and Mohammadi, M.-R. and Akhondzadeh, S. (2018) Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. Journal of Psychiatric Research, 103. pp. 104-111.
Khalaj, M. and Saghazadeh, A. and Shirazi, E. and Shalbafan, M.-R. and Alavi, K. and Shooshtari, M.H. and Laksari, F.Y. and Hosseini, M. and Mohammadi, M.-R. and Akhondzadeh, S. (2018) Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. Journal of Psychiatric Research, 103. pp. 104-111.
Ghazizadeh-Hashemi, M. and Ghajar, A. and Shalbafan, M.-R. and Ghazizadeh-Hashemi, F. and Afarideh, M. and Malekpour, F. and Ghaleiha, A. and Ardebili, M.E. and Akhondzadeh, S. (2018) Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. Journal of Affective Disorders, 232. pp. 127-133.
Ghazizadeh-Hashemi, M. and Ghajar, A. and Shalbafan, M.-R. and Ghazizadeh-Hashemi, F. and Afarideh, M. and Malekpour, F. and Ghaleiha, A. and Ardebili, M.E. and Akhondzadeh, S. (2018) Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. Journal of Affective Disorders, 232. pp. 127-133.
Divsalar, P. and Noorbala, A.A. and Moazen-Zadeh, E. and Jafarinia, M. and Shakiba, M. and Shahmansouri, N. and Ghazizadeh-Hashemi, M. and Etesam, F. and Akhondzadeh, S. (2018) Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: Placebo-controlled trial. Advances in Integrative Medicine.
Divsalar, P. and Noorbala, A.A. and Moazen-Zadeh, E. and Jafarinia, M. and Shakiba, M. and Shahmansouri, N. and Ghazizadeh-Hashemi, M. and Etesam, F. and Akhondzadeh, S. (2018) Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: Placebo-controlled trial. Advances in Integrative Medicine, 5 (2). pp. 69-74.
Milajerdi, A. and Jazayeri, S. and Hashemzadeh, N. and Shirzadi, E. and Derakhshan, Z. and Djazayeri, A. and Akhondzadeh, S. (2018) The effect of saffron (Crocus sativus L.) hydroalcoholic extract on metabolic control in type 2 diabetes mellitus: A triple-blinded randomized clinical trial. Journal of Research in Medical Sciences, 23 (2).
Milajerdi, A. and Jazayeri, S. and Hashemzadeh, N. and Shirzadi, E. and Derakhshan, Z. and Djazayeri, A. and Akhondzadeh, S. (2018) The effect of saffron (Crocus sativus L.) hydroalcoholic extract on metabolic control in type 2 diabetes mellitus: A triple-blinded randomized clinical trial. Journal of Research in Medical Sciences, 23 (2).
Esalatmanesh, S. and Abrishami, Z. and Zeinoddini, A. and Rahiminejad, F. and Sadeghi, M. and Najarzadegan, M.-R. and Shalbafan, M.-R. and Akhondzadeh, S. (2016) Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive�compulsive disorder: A placebo-controlled, double-blind, randomized trial. Psychiatry and Clinical Neurosciences, 70 (11). pp. 517-526.
Rabbani, B. and Nakaoka, H. and Akhondzadeh, S. and Tekin, M. and Mahdieh, N. (2016) Next generation sequencing: Implications in personalized medicine and pharmacogenomics. Molecular BioSystems, 12 (6). pp. 1818-1830.
Mostafavi, S.-A. and Keshavarz, S.A. and Mohammadi, M.R. and Hosseini, S. and Eshraghian, M.R. and Hosseinzadeh, P. and Chamari, M. and Sari, Z. and Akhondzadeh, S. (2016) Reliability and validity of the persian version of compulsive eating scale (CES) in overweight or obese women and its relationship with some body composition and dietary intake variables. Iranian Journal of Psychiatry, 11 (4). pp. 250-256.
Jeddi, M.Z. and Janani, L. and Memari, A.H. and Akhondzadeh, S. and yunesian, M. (2016) The role of phthalate esters in autism development: A systematic review. Environmental Research, 151. pp. 493-504.
Shalbafan, M. and Mohammadinejad, P. and Shariat, S.-V. and Alavi, K. and Zeinoddini, A. and Salehi, M. and Askari, N. and Akhondzadeh, S. (2015) Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial. Pharmacopsychiatry, 48 (4-5). pp. 136-140.
